Minireviews
Copyright ©The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastrointest Oncol. Sep 15, 2021; 13(9): 1157-1163
Published online Sep 15, 2021. doi: 10.4251/wjgo.v13.i9.1157
Effect of oncometabolic surgery on gastric cancer: The remission of hypertension, type 2 diabetes mellitus, and beyond
Yu-Xi Cheng, Dong Peng, Wei Tao, Wei Zhang
Yu-Xi Cheng, Dong Peng, Wei Tao, Wei Zhang, Department of Gastrointestinal Surgery, The First Affiliated Hospital of Chongqing Medical University, Chongqing 400016, China
Author contributions: Cheng YX and Peng D contributed equally to this work; Zhang Wei conducted quality evaluation; Peng D and Cheng YX conducted data extraction; Tao Wei conducted figure painting; Cheng YX wrote the manuscript; Peng D, Cheng YX, Tao W and Zhang W conducted writing review and editing; all authors read and approved the final manuscript.
Conflict-of-interest statement: The authors declare that they have no competing interests.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Wei Zhang, PhD, Surgeon, Department of Gastrointestinal Surgery, The First Affiliated Hospital of Chongqing Medical University, No. 1 Youyi Road, Yuanjiagang, Yuzhong District, Chongqing 400016, China. cyzhangwei@hotmail.com
Received: May 27, 2021
Peer-review started: May 27, 2021
First decision: June 16, 2021
Revised: June 24, 2021
Accepted: July 29, 2021
Article in press: July 29, 2021
Published online: September 15, 2021
Processing time: 106 Days and 3.5 Hours
Abstract

This review summarizes the definition and surgical methods of oncometabolic surgery according to previous studies. Then, the authors discuss the beneficial effects observed after gastrectomy in gastric cancer (GC) patients with concurrent hypertension or type 2 diabetes mellitus (T2DM). The authors summarize the current studies analyzing the remission rate and the hypotheses of the mechanisms underlying these effects. The remission rate ranged from 42.5%-65.4% in T2DM patients and from 11.1%-57.6% among those with hypertension. Furthermore, the remission of T2DM could have an impact on overall survival rates as well. The mechanisms underlying the remission of hypertension and T2DM is unclear in current studies, but oncometabolic surgery is expected to be applied in clinical practice. In addition, the effect of oncometabolic surgery on other chronic metabolic comorbidities is expected to be proven in further studies. Therefore, the purpose of this review is to discuss the effects of oncometabolic surgery reported in current studies with a primary focus on the remission of hypertension and T2DM after gastrectomy in GC patients. The possibility of the remission of other metabolic comorbidities in GC patients who undergo oncometabolic surgery is also discussed.

Keywords: Gastric cancer; Type 2 diabetes mellitus; Hypertension; Remission; Oncometabolic surgery

Core Tip: The purpose of this review is to discuss the effects of oncometabolic surgery observed in current studies, mainly including the remission of hypertension and type 2 diabetes mellitus after gastrectomy in gastric cancer (GC) patients, and to evaluate the possibility of the remission of other metabolic comorbidities in GC patients who undergo oncometabolic surgery.